Navigation Links
Colitis Study Shows Curcumin More Powerful When Combined with Turmeric Essential Oil
Date:4/13/2017

DALLAS, April 13, 2017 /PRNewswire/ -- In a first-of-its-kind study, published April 11, 2017 in Nature: Scientific Reports, scientists at the Baylor Scott & White Research Institute and Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas, reported that curcumin combined with turmeric essential oil is significantly more powerful than curcumin alone in attenuating the disease activity in an experimental mouse model of colitis. Ulcerative colitis is a major chronic inflammatory bowel disease affecting the entire colorectum.

"This is the first study that highlights the superiority of curcumin combined with essential turmeric essential oils (curcumin-ETO) over standard curcumin. We have shown that although curcumin works in this animal model of colitis, the essential oils delivered with the curcumin make it much more effective. There is a growing body of data that indicate that the essential turmeric oils, containing compounds called turmerones, also possess significant anti-inflammatory properties," states corresponding author Ajay Goel, Ph.D., Director, Center for Gastrointestinal Research and Director, Center for Translational Genomics and Oncology, Michael A Ramsay Chair in Cancer Genomics at the Baylor Scott & White Research Institute and Charles A. Sammons Cancer Center.

The study used BCM-95 Curcumin, which is a patented complex of curcumin and essential turmeric oils (ETO) compared to Sigma's standard curcumin. While both curcumin and curcumin with essential turmeric oil reduced the severity of colitis, the curcumin ETO group was significantly better at maintaining a healthy body weight, and showed a significant trend to less severe intestinal bleeding.

"Though the ETO-curcumin was better absorbed than plain curcumin, its beneficial activities were not solely the result of absorption, but rather the anti-inflammatory synergism of both compounds. Collectively, these data indicate that ETO-curcumin resulted in superior anti-inflammatory effects compared to standard curcumin, suggesting that the presence of ETO may synergistically enhance the bioactivity of curcumin in the colon," Goel stated.

Past human and animal studies have shown the anti-inflammatory and anti-cancer activity of ETO-curcumin, but this is the first time it has been compared directly with curcumin to examine the magnitude of increased activity.

The study concludes: "First, we confirmed anti-inflammatory properties of curcumin on the disease activity index in an animal model of DSS-induced colitis. Second, our data indicates that ETO curcumin displayed a superior anti-inflammatory efficacy than that of standard curcumin and the subsequent mathematical analysis revealed that the ETO-curcumin associated anti-inflammatory effects were particularly pronounced at higher doses. Third, further investigation of the mechanisms by which ETO-curcumin exerted anti-inflammatory effects showed that ETO curcumin upregulated anti-inflammatory cytokines including IL-10 and IL-11 and suppressed the chemokine CCL17 when compared to standard curcumin."
Full study available at: http://www.nature.com/articles/s41598-017-00812-6

Published in Nature: Scientific Reports
Essential turmeric oils enhance anti-inflammatory efficacy of curcumin in dextran sulfate sodium-induced colitis. Shusuke Toden, Arianne L. Theiss, Xuan Wang and Ajay Goel. April 11, 2017.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/colitis-study-shows-curcumin-more-powerful-when-combined-with-turmeric-essential-oil-300439498.html


'/>"/>
SOURCE Ajay Goel, Ph.D.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Second Genome Announces Agreement with Janssen on Microbiome Drug Discovery in Ulcerative Colitis
2. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
3. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
4. Takedas New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
5. U.S. Gastroenterologists Have Increased Their TNF-alpha Inhibitor Use Since 2012, Especially for AbbVies Humira, as a Result of Its Recent Approval in Ulcerative Colitis
6. Opportunity Exists in the U.S. for Novel Agents in Crohns Disease and Ulcerative Colitis, Owing to Discontinued Use of Leading Anti-TNF Agents Driven by Efficacy Failures
7. When Prescribing New Drugs for Crohns Disease or Ulcerative Colitis, Surveyed EU5 Gastroenterologists Will Prioritize Remission Rates Over Cost and Reimbursement Hurdles
8. Takeda Announces Extension of FDA PDUFA Action Date for Vedolizumab for Ulcerative Colitis
9. Altheus Therapeutics announces completed enrollment of ZA201, a Phase 2 clinical trial of Zoenasa for distal ulcerative colitis
10. Genetic And Microbiome Discoveries Point The Way To New Treatments For Crohns & Colitis Patients
11. The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohns Disease and Ulcerative Colitis Treatment Paradigm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2017)... and INDIANAPOLIS , June 9, 2017 ... with diabetes. In a further effort to help spread ... by this condition, the International Diabetes Federation (IDF) and ... have come together for the second phase of the ... programme (BRIDGES 2), reaffirming their commitment to helping people ...
(Date:6/8/2017)... , June 8, 2017  StatLab Medical ... developer and manufacturer of diagnostic supplies for ... that Cressey & Company LP ("Cressey & ... completed a growth-focused investment in the Company. ... ownership position from selling shareholder, Prairie Capital, ...
(Date:6/7/2017)... 2017  Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, ... Iowa location. The ... features an ISO 7 cleanroom—the standard needed to compound intravenous (IV) ... level of pollutants. "Our new ... better serve our Iowa patients," said ...
Breaking Medicine Technology:
(Date:6/25/2017)... (PRWEB) , ... June 25, 2017 , ... CareSet Labs ... in New Orleans. This is a new, greatly improved version of the Doctor ... Act (FOIA) requests by Fred Trotter and subsequently called the the “Doctor Referral Dataset” ...
(Date:6/24/2017)... ... June 24, 2017 , ... The Pennsylvania Athletic Trainers’ Society’s ... and Erie Convention Center on June 8-10. The weekend consisted of many ... award and scholarship presentations, and professional networking. , On Friday June 9th, ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode ... of Care Management Alerts and Dashboards, an innovative new service enabling healthcare providers ... RIQI’s Care Management Alerts and Dashboards provide near real-time data about patients admitted ...
(Date:6/23/2017)... ... June 24, 2017 , ... Studies show evidence that carotenoids and ... of visual loss in these patients. , But how often do ophthalmologists and optometrists ... to patients at risk of or with early symptoms of AMD? A study ...
(Date:6/23/2017)... ... ... Everybody has their own personal preference when it comes to pornography. Some ... don't like it at all. FindaTopDoc took a look at what makes people attracted ... readers a taste of their deepest, darkest fantasies and has the ability to help ...
Breaking Medicine News(10 mins):